Compound Profile

Semaglutide

GLP-1 receptor agonist (prescription drug)

Semaglutide is a GLP 1 receptor agonist, FDA approved as Ozempic, Wegovy, and Rybelsus, backed by a large multi trial Phase 3 program spanning weight management, type 2 diabetes, cardiovascular risk reduction, and kidney outcomes — a categorically stronger evidence tier than the RUO peptides elsewhere in this series.

Last reviewed: Report a correctionProfile-wide ·Unassigned

Use extra caution — Common side effects are nausea, vomiting, diarrhea, and constipation, most pronounced during dose escalation. Details

Typical onset
Varies by prep
Safety rating
Use extra caution: Use caution
Best for
GLP 1 Receptor Agonism, Glucose Dependent Insulin Secretion, Glucagon Suppression
Avoid / review if
Pregnancy/Breastfeeding, History Of Pancreatitis, Severe Gastrointestinal Disease Or Gastroparesis
Next steps

Continue reading

Semaglutide monograph visual
Generated profile category visual

Prescription drug: approved-product and compounding rules are separate

Semaglutide is used in FDA-approved prescription products including Ozempic, Wegovy, and Rybelsus. FDA determined the semaglutide injection shortage was resolved on February 21, 2025, so shortage-based enforcement discretion for routine essentially-copy compounding has ended; 503A and 503B still operate under different statutory conditions.

  • 503A patient-specific compounding is subject to conditions including restrictions on regularly or inordinate amounts making products that are essentially copies of commercially available drugs.
  • FDA states semaglutide is not currently on the 503B bulks list and is not on the drug-shortage list; FDA’s April 30, 2026 proposal to exclude it from the 503B bulks list is a proposal, not a final blanket rule.
  • Compounded semaglutide is not FDA-approved and does not automatically inherit the approved products’ quality or clinical evidence.

Regulatory status

2026 federal and state regulatory context

Last checked 2026 06 30

FDA approved and commercially available by prescription. The FDA has determined semaglutide is no longer in shortage, curtailing 503B outsourcing facilities' ability to compound it in bulk; compounded access now generally requires individualized physician documented clinical necessity rather than cost or availability alone. Not sold as a research peptide.

Regulatory changelog

  • 2026: FDA shortage determination resolved for semaglutide, winding down the compounded supply era; 503B bulk compounding no longer available absent individualized clinical justification.

Safety

Safety & Cautions

Common side effects are nausea, vomiting, diarrhea, and constipation, most pronounced during dose escalation. Less common but notable: gallbladder disease, rare pancreatitis, and aspiration risk under anesthesia due to delayed gastric emptying.

High caution

Caution level: High. Multiple caution categories apply, or the record uses avoid/contraindication language.

  • Hormonal Activity ContextHormone-adjacent wording is present and should be interpreted carefully.
  • Stimulant-Like ProfileStimulant-like or activating caution language is present.
  • Pregnancy/Breastfeeding CautionPregnancy or breastfeeding caution language is present.

Evidence-based safety

Caution when combined

Severity and certainty are shown separately. A high-priority caution can still be theoretical: these pairings are screened from shared contraindication mechanisms and are not automatically documented clinical interactions. Provenance identifies the source fields that produced each flag; it does not upgrade the certainty of the pairwise claim.

Moderate Caution

110 flagged pairings

Blood-sugar lowering

Representative pairings are shown below. Large mechanism groups are intentionally summarized to keep profiles focused and crawl-efficient.

Blood-sugar loweringCertainty: Theoretical

Data provenance recorded for 110 of 110 pairings in this mechanism group.

+98 more pairings share this mechanism. Use the Safety Checker to review a specific combination.

Evidence Summary

Profile-wide ·Unassigned

Evidence lens

Treat this profile as unresolved until source review is complete.

Needs reviewNeeds review

Human clinical evidence: Not the primary signal

Mechanistic / preclinical: Mechanism mapped — GLP 1 Receptor Agonism · Glucose Dependent Insulin Secretion · Glucagon Suppression

Research maturity: Theoretical / mechanistic research — Mechanistic or unresolved evidence is kept separate from established human outcomes.

Safety boundary: Safety note available — Common side effects are nausea, vomiting, diarrhea, and constipation, most pronounced during dose escalation.

Evidence Strength

Confidence estimate based on the design quality and consistency of published clinical trials.

Needs review

Semaglutide has an evidence rating that is still under review.

General wellnessGeneral wellness
Effects
4
How evidence grades work

Each grade reflects the strength and consistency of published human evidence — not marketing claims. Grades are based on study count, design quality, effect size, consistency, and recency.

Strong
Multiple RCTs, consistent direction, adequate effect size
Moderate
Some RCTs or consistent observational data in humans
Preliminary / Mixed
Animal or in-vitro only, or conflicting human data
Traditional / Theoretical
Traditional use only; no controlled human trials

How Semaglutide Works

Simplified mechanism pathway based on preclinical and pharmacological evidence. Does not confirm clinical efficacy.

Mechanism Pathway — How Semaglutide Works

How Semaglutide WorksSemaglutide acts on biological target pathways via incretin (signalling), leading to glp 1 receptor agonism.SemaglutideBiological TargetBiological pathwayIncretinSignallingGlp 1 Receptor AgonismObservable outcome
CompoundTarget / ReceptorMechanismEffect / Outcome

Dosing

No standardized dose
No established consumer dosing protocol; see full guide article for regulatory and safety context.
Mechanisms & biological pathways

Preclinical mechanism details from scientific profiles; these represent plausible pathways but do not guarantee clinical efficacy in humans.

  • GLP 1 Receptor Agonism
  • Glucose Dependent Insulin Secretion
  • Glucagon Suppression
  • Central Appetite Regulation
  • Incretin Signaling

Compare & Sourcing

Compare side-by-side tradeoffs or verify active marker guidelines.

Sourcing options disabled for safety

Direct product recommendations and affiliate links are suppressed for this compound due to its high caution or needs-review safety classification.

Evaluate the safety checks, contraindications, and potential medication interactions above under clinician supervision before use.

Safety first · Harm reduction

This information is educational and not medical advice. Start low, avoid risky combinations, and consult a licensed clinician before making health decisions—especially if you use medications, have diagnosed conditions, or are pregnant/breastfeeding.

Learn how we evaluate confidence, safety, and intensity on the methodology page.

By Willie B. Randolph III

Founder & Head Researcher · Oak Ridge, TN · Last reviewed August 2026

Editorial Review

Checked against primary sources, cited evidence, and contraindication language before publication. Evidence claims, safety language, and affiliate modules are reviewed independently. Not personal medical advice.

Editorial Standards →

Help improve this profile

Was this useful for your research?

These controls record only the page and the structured choice you make when analytics consent is enabled. Please don’t include personal medical information in research requests.

Was this evidence summary clear?

Did you find what you were researching?

Suggest an ingredient, comparison, or study →

Free safety checklist

Get the Semaglutide evidence notes

Occasional research updates, safety context, and product-quality checks for supplement decisions.

We use your email to send the checklist and occasional evidence-first supplement updates. Unsubscribe anytime. Privacy policy.

← Back to compounds librarySafety checker →